Claris Lifesciences gains on MHRA nod for new plant
This will help in enhancing capacities to grow in the regulated markets, especially the European region, Claris said.
 "Claris Lifesciences gains on MHRA nod for new plant")
Claris Lifesciences is trading 4% higher at Rs 182 on BSE after the company announced that it has received the MHRA approval for its newly commissioned plant.
This will help in enhancing capacities to grow in the regulated markets, especially the European region, Claris said in a statement.
The stock opened at Rs 182 and touched a high of Rs 186 so far on the Bombay Stock Exchange.
Around 86,000 shares changed hands on the counter in first 45 minutes of trading compared to an average 96,000 shares that were traded daily in past two weeks on BSE.
This will help in enhancing capacities to grow in the regulated markets, especially the European region, Claris said in a statement.
The stock opened at Rs 182 and touched a high of Rs 186 so far on the Bombay Stock Exchange.
Around 86,000 shares changed hands on the counter in first 45 minutes of trading compared to an average 96,000 shares that were traded daily in past two weeks on BSE.